TCGA-CF-A47V-01A-11R-A23W-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.45072273
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- ANGIOGENESIS+0.350
- KRAS_SIGNALING_DN+0.340
- INTERFERON_GAMMA_RESPONSE+0.290
- HEDGEHOG_SIGNALING+0.270
- MYOGENESIS+0.200
- APICAL_SURFACE+0.180
- KRAS_SIGNALING_UP+0.170
- COAGULATION+0.140
- PANCREAS_BETA_CELLS+0.140
Top 10 suppressed
- MYC_TARGETS_V1-0.670
- E2F_TARGETS-0.640
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V2-0.620
- PROTEIN_SECRETION-0.600
- UNFOLDED_PROTEIN_RESPONSE-0.560
- MTORC1_SIGNALING-0.550
- OXIDATIVE_PHOSPHORYLATION-0.510
- MITOTIC_SPINDLE-0.440
- DNA_REPAIR-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0XEG6SNV | EPN | Supratentorial EPN | 0.914 |
| 2 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.903 |
| 3 | TCGA-97-A4M5-01A-11R-A24X-07 | — | cohortA1 | 0.903 |
| 4 | SRR1489155 | GTEX | — | 0.902 |
| 5 | MNG690 | — | — | 0.898 |
| 6 | 20040065.TNBC | — | D | 0.896 |
| 7 | TCGA-86-A4P7-01A-11R-A24X-07 | — | cohortA1 | 0.894 |
| 8 | TCGA-97-A4M7-01A-11R-A24X-07 | — | cohortA1 | 0.894 |
| 9 | BS_GTZCFGRZ | Ganglioglioma | — | 0.892 |
| 10 | TCGA-49-AARN-01A-21R-A41B-07 | — | cohortA1 | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |